Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00197951
Status:
COMPLETED
Last Update Posted:
2007-04-23
First Post:
2005-09-12
Brief Title:
Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism
Sponsor:
Fundació Institut de Recerca de lHospital de la Santa Creu i Sant Pau
Organization:
Fundació Institut de Recerca de lHospital de la Santa Creu i Sant Pau
Study Overview
Official Title:
Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Not Being a Severe Mental Disorder Associated to Alcohol Dependence Disorder
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Alcohol dependent patients show comorbid psychiatric symptoms related to malfunction of dopamine norepinephrine and serotonin neurotransmission during early recovery Ziprasidone can improve malfunctioning of these disregulated systems thereby improving anxiety depression anhedonia anger and alcohol craving
Detailed Description:
60 alcohol-dependent patients will be included once finished alcohol detoxification treatmentThirty patients will receive ziprasidone treatment in progressively increasing doses starting from 40 mg per day and the other 30 patients will receive placebo in a double blind procedure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None